Clinical Topics & News

Screening for Psoriatic Arthritis in Psoriasis Patients

Author and Disclosure Information

 

References

Delayed diagnosis of psoriatic arthritis (PsA) can have profound effects, such as irreversible joint damage, poor quality of life, and decreased response to treatment; however, many cases of PsA are not diagnosed until up to 2 years after onset of symptoms. Dr. Saakshi Khattri discusses screening questions for PsA that dermatologists should address when treating patients with psoriasis and emphasizes that collaboration between dermatologists and rheumatologists is essential to early diagnosis and treatment of PsA.

The psoriasis audiocast series is created in collaboration with Cutis® and the National Psoriasis Foundation®.

Recommended Reading

EULAR: Panel previews updated CVD recommendations
MDedge Dermatology
Lasting ustekinumab benefits seen in psoriatic arthritis
MDedge Dermatology
Amgen’s termination of brodalumab stuns psoriasis world
MDedge Dermatology
VIDEO: Could a deep Koebner phenomenon trigger psoriatic arthritis?
MDedge Dermatology
WCD: Ixekizumab beats etanercept for psoriatic itch
MDedge Dermatology
WCD: IL-23p19 inhibitors yield ‘promising’ psoriasis results
MDedge Dermatology
WCD: Secukinumab shows effectiveness for nail, palmoplantar psoriasis
MDedge Dermatology
EULAR’s psoriatic arthritis recommendations gain new drugs
MDedge Dermatology
Clinical Trial Update: Topical Therapy for Plaque Psoriasis
MDedge Dermatology
Guselkumab prevails in phase II psoriasis trial
MDedge Dermatology

Related Articles